The UNITE4TB project, new consortium in which IRD is a partner, aims to advance tuberculosis research and enable the development of new, safe and affordable treatment solutions for tuberculosis patients worldwide.
Tuberculosis is one of the ten leading causes of death worldwide and the leading cause of death from a single infectious agent (after HIV/AIDS). The growing emergence of multidrug-resistant TB is recognised as a public health challenge and has led to new interest and investment in tuberculosis drug development.
Launched on 15 July 2021, UNITE4TB brings together 30 partners from 13 countries for 7 years. With a budget of €185 million, the project aims to accelerate and improve the clinical evaluation of existing and new drug combinations in order to develop new treatments for resistant tuberculosis.
This partnership is part of the Innovative Medicines Initiative (IMI), a European public-private research and development consortium for improve the development of new drugs to treat or prevent resistant bacterial infections.
IRD is particularly involved in the development of new clinical trial protocols. As current treatments for resistant tuberculosis are long and costly, new methodologies are being studied in order to define the best drug combination with an optimal treatment duration.
His role will also be to present them to the European (EMA) and American (FDA) clinical trial regulatory agencies in order to obtain their scientific opinion and to finalise the protocols before implementing these clinical studies.